Xeris Biopharma Holdings, Inc. Research And Development Expense

Quick Answer

Xeris Biopharma Holdings, Inc. reported Research And Development Expense of $31.17 million for the year ending 2025.

  • Xeris Biopharma Holdings, Inc. showed an increase of +21.9% in Research And Development Expense from 2024 to 2025.
  • This data is from Xeris Biopharma Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
  • XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2020 to 2025), Xeris Biopharma Holdings, Inc.'s Research And Development Expense has grown by 49.0%.
  • Historical annual values: Fiscal year 2025: $31.17 million | Fiscal year 2024: $25.56 million | Fiscal year 2023: $22.34 million | Fiscal year 2022: $20.97 million | Fiscal year 2021: $25.16 million | Fiscal year 2020: $20.92 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: